Catégorie : Non classé

Therapeutic Satisfaction and Subjective Effects of Different Strains of Pharmaceutical-Grade Cannabis, Tibor M. Brunt et al., 2014

Therapeutic Satisfaction and Subjective Effects of Different Strains of Pharmaceutical-Grade Cannabis Tibor M. Brunt, Marianne van Genugten, Kathrin Honer-Snoeken, Marco J. van de Velde, and Raymond J.M. Niesink Journal of Clinical Psychopharmacoly, 2014, 34, 344Y349 Doi : 10.1097/JCP.0000000000000129   Abstract : In The Netherlands, pharmaceutical-grade cultivated cannabis is distributed for medicinal purposes as commissioned by the Ministry of Health. Few studies have thus far described its therapeutic efficacy or subjective (adverse) effects in patients. The aims of this study are to assess the therapeutic satisfaction within a group of patients using prescribed pharmaceutical-grade cannabis and to compare the subjective effects among the available strains with special [...]

Lire la suite

Chapter 12 : Gnosis Potency : DMT Breakthroughs and Paragnosis, Graham St John, 2018

Chapter 12 : Gnosis Potency : DMT Breakthroughs and Paragnosis Graham St John in B. C. Labate, C. Cavnar (eds.), "Plant Medicines, Healing and Psychedelic Science", Springer International Publishing AG, part of Springer Nature 2018 doi : 10.1007/978-3-319-76720-8_12   Abstract DMT (N,N-dimethyltryptamine) is a powerful tryptamine that has experienced growing appeal in the last decade, independent from ayahuasca, the Amazonian visionary brew in which it is an integral ingredient. Investigating user reports available from literary and online sources, this chapter focuses on the gnosis potency associated with the DMT “breakthrough” experience. I explore the parameters of the tryptaminal state and, in particular, the extraordinary paragnosis associated with [...]

Lire la suite

Cannabis and the developing brain : Insights from behavior, Viviana Trezza et al., 2008

Cannabis and the developing brain : Insights from behavior Viviana Trezza, Vincenzo Cuomo, Louk J.M.J. Vanderschuren European Journal of Pharmacology, 2008, 585, 441-452. Doi : 10.1016/j.ejphar.2008.01.058   A B S T R A C T The isolation and identification, in 1964, of delta-9-tetrahydrocannabinol (THC), the primary psycho-active compound in cannabis, opened the door to a whole new field of medical research. The exploration of the therapeutic potential of THC and other natural and synthetic cannabinoid compounds was paralleled by the discovery of the endocannabinoid system, comprising cannabinoid receptors and their endogenous ligands, which offered exciting new insights into brain function. Besides its well-known involvement in specific [...]

Lire la suite

A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol : Δ9-Tetrahydrocannabiphorol, Cinzia Citti et al., 2019

A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol : Δ9-Tetrahydrocannabiphorol Cinzia Citti, Pasquale Linciano, Fabiana Russo, Livio Luongo, Monica Iannotta, Sabatino Maione, Aldo Laganà, Anna Laura Capriotti, Flavio Forni, Maria Angela Vandelli, Giuseppe Gigli & Giuseppe Cannazza Scientific Reports, 2019, 9, 20335 doi : 10.1038/s41598-019-56785-1 2   (-)-Trans-Δ9-tetrahydrocannabinol (Δ9-THC) is the main compound responsible for the intoxicant activity of Cannabis sativa L. The length of the side alkyl chain influences the biological activity of this cannabinoid. In particular, synthetic analogues of Δ9-THC with a longer side chain have shown cannabimimetic properties far higher than Δ9-THC itself. [...]

Lire la suite

Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats, Marcello Solinas et al., 2006

Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats Marcello Solinas, Zuzana Justinova, Steven R. Goldberg and Gianluigi Tanda Journal of Neurochemistry, 2006, 98, 408–419. doi:10.1111/j.1471-4159.2006.03880.x   Abstract Although endogenous cannabinoid systems have been implicated in the modulation of the rewarding effects of abused drugs and food, little is known about the direct effects of endogenous ligands for cannabinoid receptors on brain reward processes. Here we show for the first time that the intravenous administration of anandamide, an endogenous ligand for cannabinoid receptors, and its longer-lasting synthetic analog methanandamide, increase the extracellular dopamine [...]

Lire la suite

Cannabis thérapeutique : en avant vers l’expérimentation, Charles Delouche, Libération, 28 juin 2019

Cannabis thérapeutique : en avant vers l'expérimentation Par Charles Delouche, Libération,  — 28 juin 2019 à 18:36 Après un an d'études, le comité scientifique spécialisé a rendu son avis définitif sur la mise en place du cannabis thérapeutique en France. La balle est désormais dans le camp de l'Agence du médicament et de la Direction générale de la santé. Cannabis thérapeutique : en avant vers l'expérimentation Dévoilé avant même la fin du cycle des auditions le mercredi 19 juin, le projet final d’expérimentation du cannabis à visée thérapeutique a été dans l’ensemble favorablement accueilli par les associations de patients. Elles étaient [...]

Lire la suite

Endocannabinoid Signaling in Autism, Bhismadev Chakrabarti et al., 2015

Endocannabinoid Signaling in Autism Bhismadev Chakrabarti, Antonio Persico, Natalia Battista, Mauro Maccarrone Neurotherapeutics, 2015, Volume 12, Issue 4, 837-847. DOI 10.1007/s13311-015-0371-9 Abstract Autism spectrum disorder (ASD) is a complex behavioral condition with onset during early childhood and a lifelong course in the vast majority of cases. To date, no behavioral, genetic, brain imaging, or electrophysiological test can specifically validate a clinical diagnosis of ASD. However, these medical procedures are often implemented in order to screen for syndromic forms of the disorder (i.e., autism comorbid with known medical conditions). In the last 25 years a good deal of information has been accumulated on the main components of [...]

Lire la suite